Penn Quantitative Imaging Resource for Pancreatic Cancer
Mission
Our mission is to facilitate the development of effective therapies for pancreatic ductal adenocarcinoma (PDA) via the applications of imaging tools. We strive to develop robust imaging tools in murine models of PDA and translate them to the clinic in settings of co-clinical imaging.
About The Website
We will be making updates over the course of the U24CA231858 project (9/2018-8/2023). As the project develops, we will share resources and imaging data produced in the project including but not limited to:
- Imaging tool library - Tools including MRI pulse programs and data analysis software developed.
- SOP library – standardized protocols for generations of orthotopic and xenograft models.
- Data repository – preclinical imaging data and IHC data; clinical imaging data and companion clinical information.
Publications
The publications below represents the first detailed evaluations of DCE-MRI’s utility for detecting PDA responses to stroma-directed therapy.
1. Shoghi K, Badea C, Blocker S, Chenevert T, Laforest R, Lewis M, Luker G, Manning H, Marcus D, Mowery Y, Pickup S, Richmond A, Ross B, Vilgelm A, Yankeelov T, Zhou R. Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine. Tomography : a journal for imaging research 2020 6(3):273-287.
2. Cao J, Pickup S, Clendenin C, Blouw B, Choi H, Kang D, Rosen M, O'Dwyer PJ and Zhou R. Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma. Clin Cancer Res. Dec. 2018 (Epub ahead of print).
3. Cao J, Song HK, Yang H, Castillo V, Chen J, Clendenin C, Rosen M, Zhou R, Pickup S. Respiratory Motion Mitigation and Repeatability of Two Diffusion-Weighted MRI Methods Applied to a Murine Model of Spontaneous Pancreatic Cancer. Tomography. 2021; 7(1):66-79. https://doi.org/10.3390/tomography7010007
News
Welcome Professor James Gee and Jeffrey Duda, PhD to join the U24 team!
September 1, 2020
Drs Gee and Duda bring in outstanding expertise in informatics and will work on resource/ data sharing aspects of the U24 project while collaborating with team members in cross-modality registration and analysis.
IRB approval of “A Randomized Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Epithelial Subtype Pancreatic Cancer (NCT03519308)”. July23, 2020
July 23, 2020
University of Pennsylvania Institutional Review Board (IRB) has approved the latest modifications of this trial including the MRI studies which are supported by the U24 resource grant. The MRI protocols on this trial has also been approved by the Center for Magnetic Resonance Imaging & Spectroscopy (CAMRIS).Dr. Peter O’Dwyer, MD is the Principal Investigator of this trial, leading an investigator team from the University of Pennsylvania Abramson Cancer Center, Memorial Sloan Kettering Cancer Center, Salk Institute, and Massachusetts General Hospital. The U24 team members who participate in this clinical study include Drs. Peter O’Dwyer, Thomas Karasic, Mark Rosen, Hee Kwon Song, Rong Zhouand James Gee.